Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaeten, Jared M.-
dc.contributor.authorLingappa, Jairam-
dc.contributor.authorBeck, Ingrid-
dc.contributor.authorFrenkel, Lisa M.-
dc.contributor.authorPepper, Gregory-
dc.contributor.authorCelum, Connie-
dc.contributor.authorWald, Anna-
dc.contributor.authorFife, Kenneth H.-
dc.contributor.authorWere, Edwin-
dc.contributor.authorMugo, Nelly-
dc.contributor.authorMakhema, Joseph-
dc.contributor.authorKiarie, James-
dc.description.abstractecent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1–infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%–2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.en_US
dc.publisherOxford University Pressen_US
dc.subjectHerpes Simplex Virusen_US
dc.subjectHIV-1 transmissionen_US
dc.titleHerpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected personsen_US
Appears in Collections:School of Medicine

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.